Tech Company Financing Transactions
Numerate Funding Round
Numerate, based in San Francisco, scored $8.2 million in investment from Atlas Venture, Lilly Ventures and private investors.
Transaction Overview
Company Name
Announced On
6/5/2014
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$8,240,487
Round
Undisclosed
Investors
Atlas Venture (Lead Investor) (Bruce Booth)
Lilly Ventures (Lead Investor) (Steven Hall)
Proceeds Purpose
Their investment recognizes the success of our novel drug design platform in solving key problems of small molecule drug discovery and will enable us to advance our lead programs in metabolic, cardiovascular and neurodegenerative diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1501 Mariposa St. 426
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Website
Email Address
Overview
Numerate engineers rather than discovers drugs. We have built and validated our Drug Engineering Process to deliver leads faster, cheaper and more predictably.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guido Lanza
Chief Scientific Officer
John Griffin
Chief Technical Officer
Brandon Allgood
Vice President
Uwe Klein
Browse more venture capital transactions:
Prev: 6/5/2014: SteadyMed Therapeutics venture capital transaction
Next: 6/5/2014: Siftit venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs